A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00907205 |
Recruitment Status :
Completed
First Posted : May 22, 2009
Last Update Posted : June 13, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced or Metastatic Solid Tumors Cancer Solid Cancers | Drug: SF1126 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 44 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors |
Study Start Date : | April 2007 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | April 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: SF1126
Twice weekly IV infusion
|
Drug: SF1126
Dose Escalating with 3+ patients in each cohort |
- To assess the dose limiting toxicities (DLTs) of SF1126 and the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose. [ Time Frame: Assessed at each visit and end of cycle 1 ]
- To assess any preliminary evidence of anti-tumor activity observed with SF1126 [ Time Frame: Through study completion or early study discontinuation ]
- To characterize the pharmacokinetics following the IV doses on Days 1 and 28 [ Time Frame: Cycle 1 Days 1 and 28 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
To qualify for enrollment, all of the following criteria must be met:
- Written informed consent.
- At least 18 years old.
- Accrual will be limited to patients with tumor types that in the opinion of the investigator is known to have PTEN loss or PI3 Kinase mutations potentially important in the biology of their cancer.
- Only patients with histologically confirmation of advanced solid malignant tumor which is refractory to standard therapies or which no standard therapy exists.
- Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Life expectancy of > or = 12 weeks.
- Female subjects are eligible to enter and participate in the study if: they are non-childbearing potential, had a hysterectomy, had a bilateral oophorectomy (ovariectomy), had a bilateral tubal ligation, post-menopausal or childbearing potential with a negative serum pregnancy test at screening and agrees to protection by IUD, vasectomized partner, complete abstinence, double barrier contraception.
- male patients with childbearing potential must agree to use adequate contraception while on study.
- patients on active therapy with well-controlled diabetes as defined by fasting glucose < 160mg/dL.
Exclusion Criteria:
- Brain metastases or spinal cord compression, unless treatment was completed at least 4 weeks before entry, and stable without steroid treatment for at least 4 weeks.
- Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count <1.5 x 10^9/L or platelet count < 100 x 10^9/L (can not be post-transfusion) or hemoglobin <9 g/dL (can be post-transfusion).
- Serum bilirubin > or = 1.2 times the upper limit of normal.
- An ALT or AST level > or = 2.5 times the upper limit of normal. If documented liver metastases are present, the ALT or AST levels must still be less than 2.5 times the upper limit of normal.
- Serum creatinine > 1.5 times the upper limit of normal or a creatinine clearance of < or = 50mL/min calculated by the Cockcroft-Gault equation.
- Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, cardiac [including life threatening arrhythmias], hepatic, or renal disease.
- Unresolved toxicity ≥CTC Grade 2 from previous anti-cancer therapy except alopecia (if applicable) unless agreed that the patient can be entered after discussion with the Medical Monitor.
- QTc prolongation defined as a QTc >450 ms for males or >470ms for females (Fridericia) for 3 consecutive ECGs; OR prior history of cardiovascular disease including heart failure that meets New York Hearth Association (NYHA) class III and IV definitions, OR history of myocardial infarction/active ischemic heart disease within one year of study entry; OR uncontrolled dysrhythmias; OR poorly controlled angina.
- Participation in a trial of an investigational agent within the prior 30 days.
- Pregnant or breast-feeding females.
- High volume peritoneal or pleural effusions requiring a tap more frequently than every 14 days.
- History of other malignancies except curatively excised carcinoma in situ of the cervix, non-melanomatous skin carcinoma or superficial bladder cancer or other solid tumors curatively treated with no evidence of disease for > or = 5 years. Other cases will be reviewed and possibly allowed if discussed with and approved by Medical Monitor.
- Patients receiving therapeutic doses of Warfarin.
- Any concurrent condition which in the investigator's opinion makes it undesirable for the subject to participate in this trial or which would jeopardize compliance with the protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00907205
United States, Arizona | |
Scottsdale Clinical Research Institute | |
Scottsdale, Arizona, United States, 85258 | |
Arizona Cancer Center | |
Tucson, Arizona, United States, 85719 | |
United States, Georgia | |
Emory Winship Cancer Institute | |
Atlanta, Georgia, United States, 30322 | |
United States, Indiana | |
Indiana University Melvin and Bren Simon Cancer Center | |
Indianapolis, Indiana, United States, 46202 |
Study Chair: | Donald L Durden, MD, PhD | SignalRX Pharmaceuticals, Inc. |
Publications of Results:
Responsible Party: | Semafore Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00907205 |
Other Study ID Numbers: |
SF1126-001-06 |
First Posted: | May 22, 2009 Key Record Dates |
Last Update Posted: | June 13, 2013 |
Last Verified: | June 2013 |
Advanced Solid Tumors Metastatic Solid Tumors PI3K PI3K Inhibitors PI3 Kinase Inhibitors |
mTORC inhibitor mTORC1 inhibitor mTORC2 inhibitor vascular targeted conjugate |
Neoplasms |